Bioorganic & Medicinal Chemistry Letters最新文献_第9页

Strengths and limitations of Ba/F3 cells in modelling FLT3-driven AML resistance Ba/F3细胞在模拟flt3驱动的AML耐药中的优势和局限性

IF 2.2 4区医学

Bioorganic & Medicinal Chemistry Letters Pub Date : 2026-02-01 Epub Date: 2025-11-01 DOI: 10.1016/j.bmcl.2025.130456

Jingmei Yang, Ran Friedman

{"title":"Strengths and limitations of Ba/F3 cells in modelling FLT3-driven AML resistance","authors":"Jingmei Yang, Ran Friedman","doi":"10.1016/j.bmcl.2025.130456","DOIUrl":"10.1016/j.bmcl.2025.130456","url":null,"abstract":"<div><div>The Ba/F3 cell line is a widely used model in kinase drug development. Such cells are transformed to depend on a certain kinase for proliferation, and the use of an inhibitor of the kinase thus prevents their growth. We used Ba/F3 cells that expressed mutated FLT3 (FLT3-ITD), a known drug target in acute myeloid leukaemia (AML), to study drug resistance against two potent and selective inhibitors (gilteritinib and FF-10101). The cells could be made resistant to the drugs in concentrations that are similar to those in the plasma of patients, but this often required multiple secondary mutations. Several novel inhibitors, designed to be active against FLT3 mutants were tested but could not inhibit the growth of the resistant Ba/F3 cells. Several hitherto unidentified mutations in FLT3 were discovered that lead to drug resistance. These mutations were further studied using computational tools in order to understand how they lead to drug resistance. The discovery of novel mutations is significant since few patients were tested upon relapse due to lack of therapeutic options. Finally, we discuss the pros and cons of the Ba/F3 cell lines in the context of AML where patients express FLT3-ITD mutations in comparison with other cell lines, when the aim is development of drugs that overcome resistance.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130456"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145436735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synthesis and antitumor activities of quaternary carbon-containing selenolactones 含季碳硒内酯的合成及抗肿瘤活性研究。

IF 2.2 4区医学

Bioorganic & Medicinal Chemistry Letters Pub Date : 2026-02-01 Epub Date: 2025-10-19 DOI: 10.1016/j.bmcl.2025.130439

Danqing Li , Yumiao Zhen , Ran Tang , Boying Wang , Haijing Zhong , Xiaojian Jiang , Ying-Yeung Yeung

引用次数: 0

α2C Adrenoceptor antagonist KMCA-0011 alleviated depressive-like behaviors in a maternal separation mouse model α2C肾上腺素受体拮抗剂KMCA-0011减轻母鼠分离模型的抑郁样行为。

IF 2.2 4区医学

Bioorganic & Medicinal Chemistry Letters Pub Date : 2026-02-01 Epub Date: 2025-11-07 DOI: 10.1016/j.bmcl.2025.130467

Kobeom Seo , Mijin Jeon , Ju Eun Han , Jinwon Hong , Do Hyeon Kim , Jung Hwan Choi , Seo Yun Jung , Kyeong-Man Kim , Dong Hyun Kim , Jong Hoon Ryu , Jae Yeol Lee

{"title":"α2C Adrenoceptor antagonist KMCA-0011 alleviated depressive-like behaviors in a maternal separation mouse model","authors":"Kobeom Seo , Mijin Jeon , Ju Eun Han , Jinwon Hong , Do Hyeon Kim , Jung Hwan Choi , Seo Yun Jung , Kyeong-Man Kim , Dong Hyun Kim , Jong Hoon Ryu , Jae Yeol Lee","doi":"10.1016/j.bmcl.2025.130467","DOIUrl":"10.1016/j.bmcl.2025.130467","url":null,"abstract":"<div><div>Despite the widespread use of monoaminergic antidepressants, their clinical efficacy is often limited by delayed onset and adverse effects. Targeting the α<sub>2C</sub> adrenoceptor (AR) has emerged as a promising strategy to overcome these limitations. Here, a series of benzoxazole and oxalamide derivatives were designed, synthesized, and biologically evaluated as potential antidepressants targeting α<sub>2C</sub> AR. Among them, <strong>11e</strong> (KMCA-0011), <strong>21b</strong> (KMCA-0002), and <strong>21e</strong> (KMCA-0028) exhibited the highest binding affinity. Molecular docking studies provided a rationale for the differences in their binding affinities. These compounds demonstrated antagonistic activity by inhibiting ERK phosphorylation without agonistic effects. In a maternal separation (MS) mouse model, all three compounds significantly alleviated depressive-like behaviors, with <strong>11e</strong> (KMCA-0011) and <strong>21e</strong> (KMCA-0028) showing the most consistent efficacy. Mechanistically, <strong>11e</strong> (KMCA-0011) increased hippocampal brain-derived neurotrophic factor (BDNF) levels and restored corticosterone-induced impairments in long-term potentiation (LTP), indicating modulation of synaptic plasticity. Additionally, <strong>11e</strong> (KMCA-0011) and <strong>21e</strong> (KMCA-0028) displayed favorable ADME profiles, including high plasma stability and minimal CYP inhibition. Given the predicted limited blood–brain barrier (BBB) permeability of <strong>21e</strong> (KMCA-0028), these results collectively identify <strong>11e</strong> (KMCA-0011) as a promising lead compound that demonstrates robust antidepressant-like activity, likely mediated through α<sub>2C</sub> AR antagonism and BDNF-dependent neuroplastic mechanisms.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130467"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145476509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synthesis of dehydroabietic acid derivatives as mast cell stabilizers 作为肥大细胞稳定剂的脱氢枞酸衍生物的合成。

IF 2.2 4区医学

Bioorganic & Medicinal Chemistry Letters Pub Date : 2026-02-01 Epub Date: 2025-11-14 DOI: 10.1016/j.bmcl.2025.130477

Tao Zeng , Wenchao Yu , Chenming Gu , Jian-Guo Fu , Motahareh Asgari , Yiming Li , Fei Qian , Chen-Guo Feng

{"title":"Synthesis of dehydroabietic acid derivatives as mast cell stabilizers","authors":"Tao Zeng , Wenchao Yu , Chenming Gu , Jian-Guo Fu , Motahareh Asgari , Yiming Li , Fei Qian , Chen-Guo Feng","doi":"10.1016/j.bmcl.2025.130477","DOIUrl":"10.1016/j.bmcl.2025.130477","url":null,"abstract":"<div><div>Mast cell degranulation plays a central role in IgE-driven allergic diseases, yet the therapeutic options for stabilizers remain limited. Rosinane diterpenoids, a class of natural polyphenols known for their anti-inflammatory properties, represent an attractive source for novel anti-allergic compounds. Dehydroabietic acid (DHAA), a member of this class, exhibits diverse biological activities, yet its potential in mast cell regulation remains unexplored. In this study, we designed and synthesized a series of novel DHAA derivatives. We evaluated their anti-allergic effects in IgE/antigen-stimulated bone marrow-derived mast cells (BMMCs), and found that compound <strong>4f</strong> significantly and dose-dependently inhibited IgE-mediated Ca<sup>2+</sup> influx and suppressed mast cell degranulation. Moreover, <em>in vivo</em> studies demonstrated that compound <strong>4f</strong> effectively attenuated passive cutaneous anaphylaxis in mice and reduced vascular leakage. These findings indicate that compound <strong>4f</strong> represents a novel mast cell stabilizer and provides a promising structural scaffold for developing new anti-allergic therapeutics.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130477"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145533824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Design, synthesis, α-glucosidase inhibitory activity, and molecular docking of novel pyrazolyl–porphyrin hybrids as potential antidiabetic agents 新型吡唑啉-卟啉复合物的设计、合成、α-葡萄糖苷酶抑制活性及分子对接

IF 2.2 4区医学

Bioorganic & Medicinal Chemistry Letters Pub Date : 2026-02-01 Epub Date: 2025-11-05 DOI: 10.1016/j.bmcl.2025.130462

Sagar Vijay Kumar Peddakotla , Suresh Lingala , Onkara Perumal , M. Amaravathi , G.V.P. Chandramoulia

{"title":"Design, synthesis, α-glucosidase inhibitory activity, and molecular docking of novel pyrazolyl–porphyrin hybrids as potential antidiabetic agents","authors":"Sagar Vijay Kumar Peddakotla , Suresh Lingala , Onkara Perumal , M. Amaravathi , G.V.P. Chandramoulia","doi":"10.1016/j.bmcl.2025.130462","DOIUrl":"10.1016/j.bmcl.2025.130462","url":null,"abstract":"<div><div>A novel series of A<sub>2</sub>B<sub>2</sub> and A<sub>4</sub> type porphyrin derivatives bearing pyrazole moieties was efficiently synthesized and structurally characterized. These pyrazolyl–porphyrins were evaluated for their α-glucosidase inhibitory activity using <em>Saccharomyces cerevisiae</em> α-glucosidase as the target enzyme. <em>In vitro</em> enzyme assays and kinetic studies revealed that compounds <strong>6c</strong>, <strong>7b</strong>, and <strong>6d</strong> exhibited inhibitory effects comparable to the standard drug Acarbose. Notably, compound <strong>6c</strong> demonstrated the highest potency, with an IC₅₀ value of (31.36 μM<strong>)</strong>, closely matching that of Acarbose (31.69 μM) under identical experimental conditions. <em>In silico</em> molecular docking studies further supported the biological data, showing that compound <strong>6c</strong> interacts with key residues within the enzyme's active site in a binding mode similar to Acarbose. These findings suggest that pyrazolyl–porphyrin hybrids, particularly compound <strong>6c</strong>, hold promise as potential α-glucosidase inhibitors for the development of antidiabetic agents.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130462"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145463285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Discovery of O-alkylated derivative of piperine as Nav1.7 channel inhibitor for the treatment of pain 发现胡椒碱o -烷基化衍生物作为治疗疼痛的Nav1.7通道抑制剂。

IF 2.2 4区医学

Bioorganic & Medicinal Chemistry Letters Pub Date : 2026-02-01 Epub Date: 2025-11-04 DOI: 10.1016/j.bmcl.2025.130461

Vikrant Nawal Vikram , Madhavi Ranawat , Aditya Singh , Shiv Kumar , Ashutosh Sharma , Shivani Yadav , Vikash Kumar , Aravind Singh Kshatri , Tadigoppula Narender

引用次数: 0

Hydantion indolinones as AANAT inhibitors 水合吲哚酮作为AANAT抑制剂。

IF 2.2 4区医学

Bioorganic & Medicinal Chemistry Letters Pub Date : 2026-02-01 Epub Date: 2025-10-30 DOI: 10.1016/j.bmcl.2025.130459

Nicole Wandrey , Jake Boley , Dirce Gómez-Galicia , Mackinzi Hill , Mason Bach , Sidney Gawrych , Mackenzie Hagemeister , Philip A. Cole , Michael A. Moxley , Allen A. Thomas

{"title":"Hydantion indolinones as AANAT inhibitors","authors":"Nicole Wandrey , Jake Boley , Dirce Gómez-Galicia , Mackinzi Hill , Mason Bach , Sidney Gawrych , Mackenzie Hagemeister , Philip A. Cole , Michael A. Moxley , Allen A. Thomas","doi":"10.1016/j.bmcl.2025.130459","DOIUrl":"10.1016/j.bmcl.2025.130459","url":null,"abstract":"<div><div>Arylalkylamine <em>N</em>-acetyltransferase (AANAT) is a key enzyme in melatonin biosynthesis and a regulator of circadian rhythm, with potential relevance to mood disorders such as seasonal affective disorder (SAD). We report a series of hydantoin indolinone-based AANAT inhibitors, developed as more stable alternatives to a previously reported rhodanine scaffold. Guided by docking studies and prior structure-activity data, we modified four regions of the molecule to improve potency. Substitution at the 5-position of the indolinone ring led to marked increases in activity, with compound <strong>5g</strong> (bearing a CH<sub>3</sub>CO<sub>2</sub>CH<sub>2</sub>- substituent) resulting in an IC₅₀ of 1.1 μM—representing a 19-fold improvement over the parent compound. Kinetic mechanism studies were also conducted with respect to acetyl-CoA and serotonin to explore inhibitor binding. These findings establish a promising starting point for the development of more potent AANAT inhibitors as chemical probes for studying melatonin's function.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130459"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Discovery of small molecule CHI3L1 inhibitors by SPR-based high-throughput screening 基于spr的高通量筛选发现小分子CHI3L1抑制剂。

IF 2.2 4区医学

Bioorganic & Medicinal Chemistry Letters Pub Date : 2026-02-01 Epub Date: 2025-11-03 DOI: 10.1016/j.bmcl.2025.130460

Longfei Zhang, Hossam Hammouda Nada Hammouda, Moustafa T. Gabr

{"title":"Discovery of small molecule CHI3L1 inhibitors by SPR-based high-throughput screening","authors":"Longfei Zhang, Hossam Hammouda Nada Hammouda, Moustafa T. Gabr","doi":"10.1016/j.bmcl.2025.130460","DOIUrl":"10.1016/j.bmcl.2025.130460","url":null,"abstract":"<div><div>Chitinase-3-like 1 (CHI3L1) is a secreted glycoprotein implicated in carcinogenesis and tumor immune evasion. Elevated CHI3L1 expression is frequently detected in cancer patients, highlighting it as a promising therapeutic target. To overcome the limited availability of small molecule CHI3L1 inhibitors, we established a surface plasmon resonance (SPR)–based high-throughput screening platform and applied it to a focused chemical library of small molecules. Primary screening identified seven hits, with compounds <strong>1–4</strong> and <strong>1–7</strong> validated as CHI3L1 binders (<em>Kd</em> = 10.4 ± 1.0 μM and 7.40 ± 0.78 μM, respectively). Both compounds disrupted the CHI3L1–galectin-3 interaction in AlphaLISA assays and engaged the CHI3L1 binding pocket in docking and molecular dynamics (MD) simulations. Importantly, functional evaluation in a multicellular 3D glioblastoma (GBM) spheroid model demonstrated that compound <strong>1–7</strong> potently reduced spheroid viability and inhibited STAT3 phosphorylation, outperforming both compound <strong>1–4</strong> and the known CHI3L1–STAT3 disruptor hygromycin B (HB). These findings validate SPR as a robust primary screening platform for CHI3L1 and demonstrate that the identified small molecule binders exert functional activity in a physiologically relevant multicellular GBM spheroid model.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130460"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of affinity-optimized peptide binders of a viral protease for chemical genetic applications 一种病毒蛋白酶亲和优化肽结合物的鉴定及其化学遗传学应用。

IF 2.2 4区医学

Bioorganic & Medicinal Chemistry Letters Pub Date : 2026-02-01 Epub Date: 2025-11-05 DOI: 10.1016/j.bmcl.2025.130463

Fernando Banales-Mejia , Emily M. Dieter , Kyler J. Radmall , Glenna W. Foight , Douglas M. Fowler , Dustin J. Maly

{"title":"Identification of affinity-optimized peptide binders of a viral protease for chemical genetic applications","authors":"Fernando Banales-Mejia , Emily M. Dieter , Kyler J. Radmall , Glenna W. Foight , Douglas M. Fowler , Dustin J. Maly","doi":"10.1016/j.bmcl.2025.130463","DOIUrl":"10.1016/j.bmcl.2025.130463","url":null,"abstract":"<div><div>Chemically-controlled genetic tools are useful for studying biological systems due to their ability to dose-dependently and temporally modulate intracellular function. Chemically-disrupted proximity (CDP) systems, which involve the pre-localization of two interacting protein components that can be disrupted with a small molecule, are complementary to more commonly used chemically-inducible dimerization (CID) systems. However, fewer CDP systems have been developed, and the genetically-encoded protein components have not been as optimized for intracellular applications. Here, we describe a transcriptional activation reporter assay for screening the intracellular interaction between the 21-amino acid peptide ANR and HCVp NS3a, which are the genetically-encoded components of a CDP system that utilizes clinically-approved antiviral drugs. We used this assay to screen a library of single amino acid substitution ANR variants and identified several that increase the intracellular interaction between ANR and NS3a. By combining affinity-optimized single substitutions, we achieved improved transcriptional activation and engineered an autoinhibited signaling switch with low basal activity. Together, our study describes a functional assay for screening genetically-encoded CDP components and a more optimized version of ANR for intracellular applications.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130463"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145457031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigation of the combinatorial anticancer effects of imidazolium-based ionic liquids and lysosomotropic detergents with cisplatin and doxorubicin 咪唑类离子液体与顺铂、阿霉素溶酶收缩剂联合抗癌效果的研究。

IF 2.2 4区医学

Bioorganic & Medicinal Chemistry Letters Pub Date : 2026-02-01 Epub Date: 2025-11-15 DOI: 10.1016/j.bmcl.2025.130474

Anastasiia Gryniukova , Sergiy Rogalsky , Petro Borysko , Diana Hodyna , Vasyl Kovalishyn , Larysa Metelytsia

{"title":"Investigation of the combinatorial anticancer effects of imidazolium-based ionic liquids and lysosomotropic detergents with cisplatin and doxorubicin","authors":"Anastasiia Gryniukova , Sergiy Rogalsky , Petro Borysko , Diana Hodyna , Vasyl Kovalishyn , Larysa Metelytsia","doi":"10.1016/j.bmcl.2025.130474","DOIUrl":"10.1016/j.bmcl.2025.130474","url":null,"abstract":"<div><div>In the context of rapidly developing resistance caused by mutations in genes that control oncogenic pathways and cancer cell survival, as well as to known and widely accessible antitumor drugs, combined strategies are critical as a modern approach to cancer therapy. The <em>in vitro</em> results from a study of several long-chain N-alkylimidazole derivatives, combined with the known anticancer drugs doxorubicin and cisplatin, using cell lines of chronic myeloid leukemia K562, neuroblastoma SK-N-DZ, and mammary gland adenocarcinoma MCF7, show that the imidazolium-based ionic liquids 1-dodecyl-3-methylimidazolium chloride (IMC<sub>12</sub>C<sub>1</sub>-Cl), 1-dodecyloxycarbonylmethyl-3-methylimidazolium chloride (IMC<sub>1</sub>CH<sub>2</sub>COOC<sub>12</sub>-Cl), and, to a lesser extent, lysosomotropic detergent 1-dodecylimidazole (IMC<sub>12</sub>) consistently stand out as the most promising across all cell lines. IMC<sub>12</sub>C<sub>1</sub>-Cl demonstrated significant reductions in cisplatin and doxorubicin doses, along with enhanced cytotoxic effects, in both K562 and SK-N-DZ cells, with DRI values of 4.36 μM for cisplatin and 15.00 μM for doxorubicin. IMC<sub>1</sub>CH<sub>2</sub>COOC<sub>12</sub>-Cl showed high DRI and synergism in MCF7 cells and moderate activity in SK-N-DZ cells. IMC<sub>12</sub>C<sub>1</sub>-Cl and IMC<sub>1</sub>CH<sub>2</sub>COOC<sub>12</sub>-Cl appear to be promising candidates for the development and evaluation of their combinatorial anticancer effects.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130474"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145538251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0